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ABSTRACT 24 
Signal transducer and activator of transcription 3 (Stat3) is a signaling node for multiple 25 
oncogenic pathways and is therefore frequently active in breast cancer. As experimental and 26 
clinical evidence reveals that progestins are key players in controlling mammary gland 27 
tumorigenesis, we studied Stat3 participation in this event. We have previously shown that 28 
progestins induce Stat3Tyr705 phosphorylation and its transcriptional activation in breast 29 
cancer cells. In the present study, we demonstrate that progestins also induce Stat3 30 
phosphorylation at Ser727 residue which occurs via activation of c-Src/p42/p44 mitogen-31 
activated protein kinase pathways in murine progestin-dependent C4HD cells and in T-47D 32 
cells. Expression of a Stat3S727A vector, which carries a serine-to-alanine substitution at 33 
codon 727, shows that Stat3Ser727 phosphorylation is required for full transcriptional 34 
activation of cyclin D1 gene expression by progestins, and for in vivo Stat3 recruitment on 35 
cyclin D1 promoter. Transfection of Stat3S727A in murine and human breast cancer cells 36 
abolished progestin-induced in vitro and in vivo growth. Moreover, we found a positive 37 
correlation between progesterone receptor expression and nuclear localization of Stat3Ser727 38 
phosphorylation in breast cancer biopsies. These data highlight Stat3 phosphorylation in 39 
Ser727 residue as a nongenomic action by progestins, necessary to promote breast cancer 40 
growth. 41 
42 
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INTRODUCTION 43 
Signal transducer and activator of transcription 3 (Stat3) belongs to a family of proteins that 44 
act as cytoplasmic signaling molecules and transcription factors following nuclear 45 
translocation (Bowman et al. 2000, Yu et al. 2004). Under physiological conditions, 46 
cytoplasmic Stats are phosphorylated on tyrosine residues by tyrosine kinase receptors after 47 
binding of growth factors (Olayioye et al. 1999, Silvennoinen et al. 1993) or by soluble 48 
tyrosine kinases of the Janus (Jak) and Src kinase families, in the case of cytokine receptor 49 
activation (Darnell, Jr. et al. 1994, Heinrich et al. 1998). Phosphorylated (p) Stats form 50 
dimers, translocate to the nuclear compartment, bind to specific DNA response elements (i.e. 51 
gamma interferon-activated sequence or GAS sites) and activate transcription. In normal cells, 52 
Stat3 activation is tightly controlled; however, constitutive Stat3 phosphorylation on tyrosine 53 
residues has been found in a wide variety of human tumors (Bowman et al. 2000). In 54 
particular, Stat3 plays a key role in mammary cancer by promoting breast tumorigenesis (Yu 55 
et al. 2004) and conferring resistance to apoptosis (Gritsko et al. 2006) and to chemotherapy 56 
(Real et al. 2002). 57 
Accumulated evidence indicates that progestins are implicated in the etiology and 58 
pathogenesis of human breast cancer. Clinical observations as well as the recent extensive, 59 
randomized, and controlled Women’s Health Initiative trial revealed that postmenopausal 60 
women who undergo a combined estrogen and progesterone hormone replacement therapy 61 
suffer a higher incidence of breast cancer than women who take estrogen alone (Beral 2003). 62 
In its classical mechanism of action, the progesterone receptor (PR) acts as a ligand-activated 63 
transcription factor on promoters containing progesterone response elements (PREs) (Tsai et 64 
al. 1994). In addition to this direct transcriptional effect, progestins are able to mediate the 65 
activation of signal transduction pathways through a rapid or nongenomic mechanism 66 
(Migliaccio et al. 1998, Boonyaratanakornkit et al. 2001). Regarding this latter mechanism, it 67 
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has been described that progestin treatment of human breast cancer cell line T-47D, activates 68 
the signal-transducing c-Src/p21ras/p42/p44 mitogen activated protein kinase (MAPK) 69 
cascade to promote cell proliferation (Ballare et al. 2003, Migliaccio et al. 1998). 70 
Interestingly, it has been shown that steroid hormone receptors regulate Stat3 levels and, 71 
conversely, Stat3 regulates transcriptional activation of steroid hormones (Richer et al. 1998, 72 
De Miguel et al. 2003). We have already demonstrated that progestins induce Stat3 73 
phosphorylation at tyrosine 705 (Tyr705) through the activation of c-Src/Jaks kinases, leading 74 
to Stat3 transcriptional activation and proliferation both in mouse and human mammary breast 75 
cancer cells (Proietti et al. 2005). These effects on c-Src and Jaks activation are dependent on 76 
the classical PR, evidencing that through a rapid signaling pathway, PR is able to activate 77 
Stat3. 78 
In addition to Tyr705 phosphorylation, a conserved serine phosphorylation site (Ser727) was 79 
also identified within the transcriptional activation domain of Stat3. Serine phosphorylation 80 
may occur in response to diverse stimuli and it modulates Stat3 transcriptional activity 81 
(Decker et al. 2000, Wen et al. 1995). However, the requirement of Stat3 phosphorylation at 82 
Ser727 to achieve a biological effect may vary according to the stimulating ligand and/or 83 
cellular context (Sasse et al. 1997). Experiments of replacement of the wild-type Stat3 allele 84 
with the Stat3S727A mutant reveal the importance of Stat3Ser727 phosphorylation in 85 
postnatal survival and growth in mice (Shen et al. 2004). Much effort has been made to 86 
identify the kinase(s) responsible for serine 727 phosphorylation of Stat3. Stat3Ser727 residue 87 
is situated in a conserved PMSP motive which resembles the consensus PxS/TP motive for 88 
MAPK targets (Gonzalez et al. 1991). Several kinases activated by a large number of ligands 89 
have been implicated in serine phosphorylation, involving an interaction between Stat3 and 90 
serine kinase signaling pathways (Decker et al. 2000). However, Stat3Ser727 phosphorylation 91 
induced by progestins and its biological significance remain unexplored. 92 
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In the present study, we found that progestin treatment of human breast cancer cell line T-47D 93 
and of murine progestin-dependent breast cancer C4HD cells induces phosphorylation of 94 
Stat3 at Ser727 residue. We also showed that progestin activation of the c-Src/p42/p44 95 
MAPK signaling pathway is directly involved in Stat3Ser727 phosphorylation and contributes 96 
to the recruitment of Stat3 to a GAS site in the cyclin D1 promoter. Prevention of Stat3 97 
phosphorylation at Ser727 residue with a Stat3S727A expression vector reveals the 98 
importance of this residue in mediating progestin-induced breast cancer cell growth. We also 99 
examined 39 primary tumor samples obtained from patients with invasive ductal breast 100 
carcinoma and observed a positive correlation between Stat3Ser727 phosphorylation and PR 101 
expression. As a whole, our data provide evidence that phosphorylation at Ser727 residue 102 
confers full transcriptional activity of Stat3 and that it is a requisite for progestin up-103 
regulation of cyclin D1, and in vivo and in vitro breast cancer growth. 104 
105 
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MATERIALS AND METHODS 106 
Animals and tumors 107 
Experiments were carried out with virgin female BALB/c mice raised at the Institute of 108 
Biology and Experimental Medicine (IBYME) of Buenos Aires (Argentina) and were 109 
maintained in pathogen-free conditions. All animal studies were conducted as described 110 
previously (Proietti et al. 2005) in accordance with the highest standards of animal care as 111 
outlined by the NIH Guide for the Care and Use of Laboratory Animals (Guide for the Care 112 
and Use of Laboratory Animals.Washington 1996), and were approved by the IBYME 113 
Animal Research Committee. The hormone-dependent ductal tumor line C4HD was 114 
originated in mice treated with 40 mg medroxyprogesterone acetate (MPA, Craveri, Buenos 115 
Aires, Argentina) every 3 months for 1 year, and has been maintained by serial transplantation 116 
in animals treated with 40 mg subcutaneously (s.c.) MPA depot in the opposite flank to tumor 117 
inoculum (Balana et al. 1999). C4HD tumor line expresses PR and estrogen receptor (ER) and 118 
lacks glucocorticoid receptor expression (Balana et al. 1999). 119 
Cell culture, treatments and proliferation assays  120 
Primary culture of epithelial cells from C4HD tumors was performed as previously described 121 
(Rivas et al. 2008). Cells were incubated in Dulbecco’s modified Eagle’s medium-Ham F12 122 
(DMEM:F12) 1:1 v/v (without phenol red) supplemented with 0.1% (v/v) charcolized fetal 123 
calf serum (ChFCS) in the presence or absence of 10 nM MPA (Sigma-Aldrich St. Louis, 124 
MO, USA) and 10 nM RU486 (Sigma). T-47D cells were obtained from the American Type 125 
Culture Collection and maintained in DMEM:F12 + 10% FCS. T-47D-Y cells were a 126 
generous gift from K. Horwitz (University of Colorado Health Sciences Center, Denver, CO, 127 
USA) (Sartorius et al. 1994). When indicated, cells were pretreated for 90 min with 10 µM 128 
U0126 (Sigma) or with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine 129 
(PP2) 10 µM (Calbiochem San Diego, CA, USA) dissolved in 1:2000 dimethyl sulfoxide, or 130 
Dasatinib 10 µM (LC Laboratories, Woburn, MA, USA) to block p42/p44 MAPK signalling 131 
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pathway or c-Src activity respectively, before the addition of MPA. Controls were performed 132 
in order to verify that dimethyl sulfoxide (1:2000) did not modify MPA-modulated c-Src 133 
tyrosine phosphorylation, p42/p44 MAPK or Ser727Stat3 phosphorylation. Cell proliferation 134 
was evaluated by a [
3
H]thymidine incorporation assay as previously described (Proietti et al. 135 
2005). Assays were performed in octuplicate. In former experiments, we have demonstrated 136 
that thymidine uptake correlates with the number of cells/well (Rivas et al. 2008). 137 
Proliferation was also evaluated by propidium iodide staining and flow cytometry analysis, as 138 
described previously (Rivas et al. 2010). Cell cycle analysis was performed using a 139 
FACScalibur flow cytometer (Becton-Dickinson, MountainView, CA, USA) and Modfit LT 140 
software. 141 
Western Blot analysis  142 
Lysates were prepared from cells subjected to the different treatments described, and proteins 143 
were subjected to SDS-PAGE as previously described (Schillaci et al. 2006). Membranes 144 
were immunoblotted with the following antibodies: total Stat3 (C-20), pp42/p44 MAPK (E-145 
4), total p42/p44 MAPK (C-14), all from Santa Cruz Biotechnology (Santa Cruz, CA, USA); 146 
pStat3Ser727 (GE4), phosphotyrosine c-Src (Tyr 416) and c-Src (36D10), from Cell 147 
Signaling (Beverly, MA, USA); PR (clone hPRa7), actin (clone ACTN05) and cyclin D1 148 
from Neomarkers (Freemont, CA, USA); β-tubulin from Sigma-Aldrich. The specificity of 149 
pStat3Ser727 (GE4) antibody for Western blot assays was previously reported (Turner et al. 150 
2009, Sud et al. 2009). Human and mouse Stat3 homologies are completely identical, except 151 
for a single amino-acid change at position 760 (Pietra et al. 1998). 152 
The NE-PER nuclear and cytoplasmic extraction reagent technique (Thermo Fisher Sci, Inc, 153 
Rockford, IL, USA) was performed according to manufacturer’s instructions and the sub-154 
cellular extracts were subjected to SDS-PAGE and immunoblotting.  155 
Transient transfections 156 
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 C4HD or T-47D cells were transiently transfected for 48 h with 2 µg of the expression 157 
vectors for Stat3S727A (pcDNA5/FRT vector  encoding a GFP-Stat3 fusion protein which 158 
carries a serine-to-alanine substitution at codon 727-GFP-Stat3S727A), and wild-type Stat3 159 
(pcDNA5/FRT vector encoding a GFP-Stat3 fusion protein ) (Lee et al. 2009).  As control, 160 
cells were transfected with 2 µg of the empty vector (pcDNA5/FRT). All these vectors were 161 
kindly provided by H. Yu (Beckman Research Institute, Duarte, CA, USA). Transfection 162 
efficiencies, evaluated by the percentage of cells that exhibited GFP 48 h after transfection, 163 
varied between 60 and 70%. C4HD cells were transfected in DMEM-F12 supplemented with 164 
10 nM MPA and 2.5% ChFCS, and T-47D cells were transfected in DMEM with 10% ChFCS 165 
without antibiotics with Fugene HD transfection reagent (Roche Biochemicals, Indianapolis, 166 
IN, USA). The plasmid encoding human wild-type hPR-B was kindly provided by K. 167 
Horwitz. Mutant PR-B engineered to convert three key prolines (P422A, P423A, and P426A) 168 
to alanines (PR-BmPro), thus abolishing PR binding to all the SH3 domains and inhibiting 169 
activation of the Src family tyrosine kinases (Boonyaratanakornkit et al. 2001), was 170 
generously provided by D. Edwards (Baylor College of Medicine, Houston, TX, USA). After 171 
transfection, cells were washed and cultured for 24 h in 0.1% ChFCS before treatment with 172 
MPA for the indicated times. Total cell lysates were then prepared as described above for use 173 
in Western blot assays. To investigate the capacity of MPA to induce the transcriptional 174 
activation of Stat3, C4HD and T-47D cells were transiently transfected for 48h with 2 µg of a 175 
luciferase reporter plasmid containing four copies of the m67 high-affinity binding site 176 
(Bromberg et al. 1999, Zhang et al. 2000) or with a luciferase reporter plasmid containing the 177 
cyclin D1 human promoter region (1745 cyclin D1-luc), kindly provided by R. Pestell 178 
(Northwestern University Medical School, Chicago, IL, USA). Cells were co-transfected with 179 
10 ng Renilla luciferase expression vector CMV-pRL (Promega, Madison, WI, USA) to 180 
Page 8 of 41
  
9
correct variations in transfection efficiency. Transfected cells were lysed and luciferase assays 181 
carried out using the Dual-Luciferase Reporter Assay System (Promega).  182 
Chromatin immunoprecipitation assays  183 
Chromatin immunoprecipitation (ChIP)  was performed as we described previously (Beguelin 184 
et al. 2010). Briefly, chromatin was sonicated to an average of about 500 bp. Sonicated 185 
chromatin was then immunoprecipitated using 4 µg of Stat3 antibody and IgG as control. The 186 
immunoprecipitate was collected using protein A beads (Millipore, Temecula, CA, USA), 187 
which were washed repeatedly to remove nonspecific DNA binding. Chromatin was eluted 188 
from the beads, and cross-links were removed overnight at 65°C. DNA was then purified and 189 
quantified using real-time PCR performed with an ABI Prism 7500 sequence detector, using 190 
SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA). Primers used 191 
were as previously described  (Beguelin et al. 2010). PCR was performed for 40 cycles with 192 
15 s of denaturing at 95°C, and annealing and extension at 60°C for 1 min. 193 
In vitro cold phosphorylation assay 194 
T47D cells were treated with 10 nM MPA for 2 min or preincubated for 90 min with 10 µM 195 
U0126 before MPA stimulation. Cells were lysed in kinase lysis buffer (20 mM HEPES pH 196 
7.5, 10 mM EGTA, 1% NP-40, 2.5 mM MgCl2) and MAPK was immunoprecipitated using 197 
anti-total p42/p44 MAPK antibody (C-14; Santa Cruz) from 500 µg protein extracts. 198 
Unphosphorylated Stat3 was immunoprecipitated from 500 µg protein extract from nontreated 199 
C4HD cells by using the Stat3 antibody (C-20, Santa Cruz). The immunoprecipitated Stat3 200 
was then subjected to an in vitro phosphorylation assay with p42/p44 MAPKs 201 
immunoprecipitated from cells subjected to each of the treatments described, following the 202 
procedure previously described (Rivas et al. 2010). Gels were transferred onto nitrocellulose. 203 
Their upper part was immunoblotted with pStatSer727 antibody while their lower part was 204 
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revealed with an anti-pp42/p44 MAPK monoclonal antibody. Filters were then stripped and 205 
hybridized with anti-total Stat3 or anti-total p42/p44 MAPK antibodies, respectively. 206 
Small interfering RNAs transfections 207 
Small interfering RNAs (siRNAs) targeting PR were synthesized by Dharmacon, Inc. 208 
(Lafayette, CO, USA) (PR siRNA 5´-AUAGGCGAGACUACAGACGUU-3´). A 209 
nonsilencing siRNA oligonucleotide from Dharmacon that does not target any known 210 
mammalian gene was used as a negative control. The transfection of siRNA duplex was 211 
performed for 3 days by using DharmaFECT transfection reagent according to manufacturer’s 212 
directions.  213 
Immunofluorescence and confocal microscopy 214 
T-47D cells grown on glass coverslips were ﬁxed and permeabilized in ice-cold methanol and 215 
were then blocked with phosphate-buffered saline (PBS) with 1% bovine serum albumin. 216 
pStat3Ser727 was localized using a mouse monoclonal (6E4) antibody (Cell Signaling), 217 
followed by incubation with a goat anti-mouse IgG-Alexa 488 (Molecular Probes, Eugene, 218 
OR, USA) secondary antibody. Negative controls were carried out using PBS instead of 219 
primary antibodies. Approximately 100 to 200 cells were analyzed for each treatment, of 220 
which around 80% showed the same pattern of Stat3 phosphorylation and cellular 221 
localization. Cells were analyzed using a Nikon Eclipse E800 confocal laser microscopy 222 
system (Beguelin et al. 2010). Nuclei were stained with propidium iodide. 223 
In vivo inhibition of Stat3 serine 727 phosphorylation 224 
C4HD cells were transiently transfected with the Stat3S727A expression vector or with the 225 
empty vector. After transfection, 10
6 
cells from each experimental group were inoculated 226 
(s.c.) into animals treated with a 40-mg MPA depot in the ﬂank opposite of the cell inoculum 227 
(n=5). Tumor growth was measured three times a week with a vernier caliper. Tumor volume 228 
(mm
3
) was calculated as (L x W
2
)/2, where L length (mm) and W width (mm). Tumor growth 229 
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rates were determined as the slopes of growth curves. Linear regression analysis was 230 
performed on tumor growth curves, and the slopes were compared by using analysis of 231 
variance followed by a parallelism test to evaluate the statistical significance of differences. 232 
Patients and Tissue Microarays  233 
Paraffin-embedded tissue samples from 48 archived invasive breast carcinomas were selected 234 
for construction of Tissue Microarays (TMAs) blocks from the files of the Instituto de 235 
Oncología Henry Moore, Buenos Aires, Argentina, from 2001 to 2008. From 9 tumor 236 
samples, immunohistochemical analysis of nuclear pStat3Ser727 levels was uninformative 237 
because of missing or unrepresentative samples in the array sections analyzed. All patients 238 
were treated with surgery. This study was conducted with the approval of ethics committees 239 
of IBYME and the Instituto de Oncología Henry Moore and informed written consents were 240 
obtained from all patients before inclusion. Pre-treatment patient staging was classified 241 
according to the system of the American Joint Committee on Cancer (AJCC) (Singletary et al. 242 
2002) through the Elston and Ellis histological grading (Page et al. 1995). TMAs were 243 
constructed as described before (Schillaci et al. 2012).  244 
Immunofluorescence and immunohistochemistry analysis of TMAs 245 
Immunofluorescence was performed as previously described (Schillaci et al. 2012), using the 246 
mouse monoclonal anti pStat3Ser727 (6E4) antibody, (dilution 1:50 overnight at 4ºC; Cell 247 
Signaling). Slides were then incubated with an anti-mouse Alexa 488-conjugated antibody 248 
(1:1000, Molecular Probes). Nuclei were stained with propidium iodide. Slides were analyzed 249 
by Nikon Eclipse E800 confocal laser microscopy system. Negative controls were carried out 250 
in the absence of primary antibodies. Staining intensity was graded on the following scale: 0, 251 
no staining; 1, weak staining; 2, moderate staining; and 3, intense staining, as previously used 252 
for nuclear pTy705Stat3 classification by other authors (Dolled-Filhart et al. 2003, Sato et al. 253 
2011). Scoring of the tissue microarray was completed by two independent observers (EM 254 
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and PG), with very high correlation between scorers. Discrepancy between them was 255 
averaged to get a single final score. A score of one (1) or more was required for tumor sample 256 
to be considered positive for nuclear pStat3Ser727 expression (Sato et al. 2011). 257 
ER and PR were evaluated by immunohistochemistry (IHC) with clone 6F11 (Novocastra 258 
Laboratories, U.K, USA) and clone hPRa2+hPRa3 (NeoMarkers), respectively, and scored as 259 
described (Schillaci et al. 2012). 260 
Statistical Analysis 261 
Western Blot bands were quantiﬁed using Image J, phosphorylated protein band values were 262 
normalized to total protein bands, and cyclin D1 bands were normalized to β-tubulin bands. 263 
Differences between control and experimental groups along this work were analyzed by 264 
ANOVA followed by Tukey t test between groups. A P <0.05 was accepted as statistically 265 
significant. 266 
Analyses of clinical data were conducted using SPSS software version 17.0 (SPSS Inc, 267 
Chicago, IL, USA). Correlations between categorical variables were performed using the 268 
Fisher’s exact test. 269 
270 
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RESULTS 271 
MPA induces Stat3Ser727 phosphorylation acting through the classical PR 272 
In this study we used the progestin-dependent C4HD tumor from an experimental model of 273 
hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate 274 
(MPA) induces mammary adenocarcinomas in female BALB/c mice (Proietti et al. 2005). We 275 
have long demonstrated that MPA is able to induce tyrosine phosphorylation of Stat3 in 276 
C4HD cells and in the human breast cancer cell line T-47D (Proietti et al. 2005). We here 277 
evaluated Ser727 phosphorylation in C4HD and T-47D cells in response to MPA. As shown 278 
in Figure 1A, MPA induced Stat3Ser727 phosphorylation within 5 min of treatment and 279 
remained elevated at 30 min in C4HD and T-47D cells. This effect was completely abolished 280 
by the progestin antagonist RU486 or by knockdown of PR gene expression with PR siRNAs 281 
in C4HD cells (Fig. 1B). Moreover, in human PR-null T-47D-Y cells, MPA treatment did not 282 
induce Stat3Ser727 phosphorylation (Fig. 1C). On the other hand, transfection of these cells 283 
with PR-B (T-47D-Y-PR-B) restores MPA ability to phosphorylate Stat3 at Ser727 residue 284 
(Fig. 1C). These results indicate that MPA regulates the rapid phosphorylation of Stat3Ser727 285 
residue through the classical PR.  286 
MPA induces Stat3Ser727 phosphorylation through the activation of c-Src/p42/p44 MAPK 287 
signaling pathway 288 
It is known that progestins induce rapid c-Src activation in mammary tumor cells, including 289 
our C4HD tumor model (Boonyaratanakornkit et al. 2001, Migliaccio et al. 1998, Proietti et 290 
al. 2005). Pioneering works defined the proline-rich domain of human PR as an absolute 291 
requirement for interaction with c-Src (Boonyaratanakornkit et al. 2001) and consequent c-292 
Src activation of signaling cascades in response to progestins (Boonyaratanakornkit et al. 293 
2001, Migliaccio et al. 1998). To explore whether c-Src was involved in progestin-mediated 294 
Stat3Ser727 phosphorylation, we transfected T-47D-Y cells with the PR-BmPro mutant, in 295 
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which three prolines (P422A, P423A, and P427A) were converted to alanines (T-47D-Y-PR-296 
BmPro cells). Figure 2A shows that T-47D-Y-PR-BmPro cells lacked the ability to 297 
phosphorylate Stat3 at Ser727 residue in response to MPA, suggesting that progestin-298 
activated c-Src acts as an upstream activator of Stat3. Moreover, the addition of the c-Src 299 
inhibitors PP2 or Dasatinib effectively inhibited Stat3Ser727 phosphorylation by MPA in T-300 
47D cells (Fig. 2B). Although it is known that murine PR lacks the polyproline sequence 301 
known to interact with c-Src, we have previously demonstrated that MPA treatment for 2 to 302 
10 min of murine C4HD cells induced strong c-Src tyrosine phosphorylation (Proietti et al. 303 
2005). Interestingly, blockage of MPA-induced c-Src activation by PP2 treatment in C4HD 304 
cells leads to inhibition of Stat3Ser727 phosphorylation in these murine cells (Fig. 2B). 305 
p42/p44 MAPK are serine/threonine kinases whose activation by progestin-induced c-Src 306 
signaling is well acknowledged (Ballare et al. 2003, Migliaccio et al. 1998). However, the 307 
role of p42/p44 MAPK in progestin-induced Stat3 activation has never been addressed. Here, 308 
we confirmed that MPA induces a rapid phosphorylation of p42/p44 MAPK in C4HD and T-309 
47D cells. MPA-induced activation was observed as early as 2 to 5 min after treatment and 310 
preceded Stat3 serine phosphorylation (Fig. 1A). Pretreatment of C4HD cells with 10 µM 311 
U0126, a p42/p44 MAPK pathway inhibitor, suppressed phosphorylation of Stat3 at Ser727 312 
residue (Fig. 2C). Blockade of c-Src activation by addition of Dasatinib or PP2, abolished 313 
p42/p44 MAPK in T-47D cells. Similar results were obtained in C4HD cells treated with PP2, 314 
suggesting that MAPK phosphorylation is dependent on c-Src activation also in murine cells 315 
(Fig. 2B). 316 
To further support our finding that the serine phosphorylation of Stat3 proceeds though the 317 
activation of p42/p44 MAPK-dependent pathway, we performed a cold in vitro 318 
phosphorylation assay. For this purpose, we immunoprecipitated p42/p44 MAPK from T-47D 319 
cells treated or not with MPA for 2 min, and from T-47D cells pretreated with U0126 for 90 320 
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min prior to MPA treatment. We also immunoprecipitated Stat3 from unstimulated cells and 321 
used it as a source of unphosphorylated Stat3 in the assay. As shown in Figure 2D, incubation 322 
of p42/p44 MAPK immunoprecipitated from T-47D cells treated with MPA with the 323 
unphosphorylated Stat3, induced phosphorylation of Stat3 at Ser727 residue. Neither p42/p44 324 
MAPK obtained from control cells nor p42/p44 MAPK inactivated by U0126 increased Stat3 325 
phosphorylation (Fig. 2D). As a whole, these results strongly suggest that p42/p44 MAPK are 326 
the kinases activated by MPA responsible for the induction of Stat3 phosphorylation at 327 
Ser727 residue.  328 
MPA promotes nuclear localization of Stat3 phosphorylated at Ser727 329 
We have already reported that MPA induces Stat3Tyr705 phosphorylation and its nuclear 330 
translocation (Proietti et al. 2005). In order to investigate the localization of Stat3 331 
phosphorylated in Ser727 induced by MPA, nuclear and cytoplasmic extracts from C4HD 332 
were prepared and evaluated by Western blot. Figure 3A shows that MPA treatment induced 333 
Stat3Ser727 phosphorylation in the cytoplasmic fraction and an increased translocation to the 334 
nuclear compartment (Fig. 3A). In addition, immunofluorescence staining and confocal 335 
microscopy studies in T-47D revealed that Stat3 phosphorylated at Ser727 is barely detected 336 
in control cells. MPA treatment for 10 or 15 min resulted in strong staining of pStat3Ser727 337 
both in the cytosol and in the nuclear compartment (Fig. 3B).  338 
MPA requires Stat3Ser727 phosphorylation to achieve maximal transcriptional activation of 339 
Stat3 340 
To address the question of whether serine phosphorylation influences the transcriptional 341 
activity of Stat3, C4HD cells were transiently co-transfected with Stat3S727A expression 342 
vector, which carries a serine-to-alanine substitution at codon 727, together with a luciferase 343 
reporter plasmid containing four copies of the m67 high-affinity binding site (4xm67-tk-luc) 344 
(Bromberg et al. 1999). As controls, cells were co-transfected with wild type (WT) Stat3 345 
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expression vector or with an empty vector, together with the reporter plasmid. As previously 346 
described, MPA stimulation induced Stat3 transcriptional activation of Stat3 (Proietti et al. 347 
2005) (Fig. 4A). Transfection of C4HD cells with Stat3S727A inhibited the capacity of MPA 348 
to activate the m67-Luc reporter plasmid (Fig. 4A). These data indicate that Stat3Ser727 349 
phosphorylation is required for MPA-induced maximal Stat3 activation. Western blots studies 350 
demonstrated similar expression of Stat3WT and Stat3S727A in C4HD transfected cells (Fig. 351 
4A, right panel) 352 
To explore the biological relevance of Stat3Ser727 phosphorylation, we studied cyclin D1 353 
promoter activation, as it is a key breast cancer cell cycle regulator, whose promoter has Stat3 354 
biding sites (Leslie et al. 2006) and lacks a progesterone response element (PRE) in its 1-kb 355 
promoter-proximal region (Skildum et al. 2005). C4HD and T47D cells were transiently 356 
transfected with a 1,745-bp human cyclin D1 promoter luciferase construct containing Stat3 357 
binding sites, named GAS sites, at positions -984, -568, -475, -239, -68, and -27. Cells were 358 
co-transfected either with an empty vector, or a Stat3WT or a Stat3S727A expression vector. 359 
MPA treatment of both cell types resulted in an increase of cyclin D1 promoter activity in 360 
cells transfected with an empty vector or with Stat3WT vector (Fig. 4B). On the other hand, 361 
transfection of cells with Stat3S727A absolutely inhibited the effects of MPA on cyclin D1 362 
promoter activation in both cell types (Fig. 4B).The reporter assays shown in Fig. 4A and B 363 
suggest that Stat3S727A vector is acting as a dominant negative of endogenous Stat3.  364 
Finally, we sought to determine the participation of Stat3Ser727 phosphorylation in the 365 
upregulation of cyclin D1 protein expression by MPA. Abolishment of Stat3Ser727 366 
phosphorylation by transfection with Stat3S727A abrogated MPA-induced cyclin D1 367 
expression in C4HD and T-47D cells (Fig. 4C). As a whole, our results indicate that Stat3 368 
requires Ser727 phosphorylation to achieve full transcriptional activity on cyclin D1 promoter 369 
and protein expression upon MPA stimulation in breast cancer cells.  370 
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Stat3Ser727 phosphorylation is required for in vivo binding of Stat3 to the promoter of cyclin 371 
D1  372 
To assess the participation of Stat3Ser727 phosphorylation on the specific association of Stat3 373 
to its binding sites in the context of living cells, we used a ChIP assay. After 30 min of MPA 374 
treatment, chromatins were immunoprecipitated using a total Stat3 antibody.  Our findings 375 
with T-47D cells transfected with an empty vector or with Stat3WT, using primers spanning 376 
the GAS site at position -948 of the human cyclin D1 promoter, showed a significant and 377 
specific MPA-induced binding of Stat3 (Fig. 4D), as was previously reported by our lab 378 
(Beguelin et al. 2010). We then questioned whether Stat3 phosphorylation in Ser727 is 379 
mandatory for Stat3 recruitment to the GAS sites of the cyclin D1 promoter. To address this 380 
issue, we transfected T-47D cells with a Stat3S727A expression vector. We observed that the 381 
absence of Stat3Ser727 phosphorylation blocked Stat3 occupancy of the GAS sites of cyclin 382 
D1 promoter. These results reveal that Stat3 phosphorylation in serine 727 residue is 383 
necessary for in vivo Stat3 recruitment to the cyclin D1 promoter after MPA treatment.   384 
Blockade of Stat3Ser727 phosphorylation inhibits in vitro and in vivo progestin-induced 385 
breast cancer growth 386 
These results led us to investigate the correlation between MPA-induced Stat3Ser727 387 
phosphorylation and cell growth. Thus, C4HD and T-47D cells were transiently transfected 388 
with Stat3WT or Stat3S727A expression vectors or with the corresponding empty vector, and 389 
proliferation was evaluated by [
3
H]-thymidine incorporation at 48h or 24h of MPA treatment, 390 
respectively. As shown in Figure 5A, expression of the Stat3S727A mutant had an inhibitory 391 
effect on MPA-induced proliferation of both human and murine breast cancer cells, compared 392 
with MPA-stimulated cells transfected with Stat3WT or an empty vector. Proliferation of 393 
transfected T-47D was also evaluated by propidium iodide staining and flow cytometry 394 
analysis, with similar results. Expression of Stat3S727A had an inhibitory effect on MPA-395 
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induced growth of T-47D cells, reflected in a cell cycle arrest in phase G1 compared with 396 
Stat3WT-transfected T-47D cells in the presence of MPA (Fig. 5B). 397 
Furthermore, we wanted to explore Stat3Ser727 requirement for in vivo progestin-driven 398 
breast cancer growth, for which we took advantage of the well-described model of murine 399 
breast cancer tumor C4HD that requires progestin for in vivo growth in BALB/c mice 400 
(Beguelin et al. 2010). C4HD cells growing in 10 nM MPA were transfected with 401 
Stat3S727A expression vector or with an empty vector. After 48h of transfection, 10
6
 cells 402 
from each experimental group were inoculated s.c. into animals treated with a 40 mg MPA 403 
depot in the flank opposite to the cell inoculum, and tumor width and length were measured 404 
three times a week for 35 days in order to calculate volume. As shown in Figure 5C, the 405 
expression of Stat3S727A in C4HD cells strongly inhibited MPA-induced tumor growth. The 406 
mean volume and growth rates of tumors that developed from Stat3S727A-C4HD cells were 407 
significantly lower than the tumors from the control group (Supplementary Table 1). At the 408 
end of the experiment, we prepared tumor extracts and explored levels of Stat3Ser727 409 
phosphorylation and cyclin D1 expression. As shown in Figure 5D, significantly lower levels 410 
of Stat3Ser727 phosphorylation and cyclin D1 were found in tumors developed in mice 411 
injected with Stat3S727A-C4HD cells than in tumors of mice injected with empty vector-412 
C4HD cells. The expression of the Stat3S727A-GFP fusion protein was not detected by 413 
Western Blot at the end of the experiment (Day 35). Histopathological analysis of tumors 414 
from Stat3S727A-C4HD cells showed extensive fibrotic areas and also displayed a marked 415 
decrease in mitotic figures when compared to tumors from empty vector-C4HD cells 416 
(Supplementary Table 1). As a whole, these results further support the direct relevance of 417 
Stat3Ser727 phosphorylation in progestin-induced in vitro an in vivo breast cancer 418 
proliferation 419 
Page 18 of 41
  
19
Ser727 phosphorylation of Stat3 is associated with PR expression in invasive ductal 420 
carcinomas  421 
Because the above-described in vitro and in vivo assays provided evidence that progestins 422 
induce Stat3Ser727 phosphorylation which is essential for up-regulating cyclin D1 expression 423 
and cell proliferation, we explored whether Stat3Ser727 phosphorylation correlates with 424 
various clinicopathological parameters in patients with invasive ductal carcinomas. TMAs 425 
from 48 tumor samples from our cohort, obtained from patients before therapy, were analyzed 426 
for nuclear expression of pStat3Ser727 by immunofluorescence using a specific antibody. 427 
Expressions of ER and PR were performed by immunohistochemistry using the 428 
corresponding antibodies. Of the 48 tumor samples on the TMAs, 39 tumor cores (82%) were 429 
interpretable for Stat3 staining. Clinical and pathological characteristics of these specimens 430 
are shown in Supplementary Table 2. Positive nuclear Stat3Ser727 staining was observed in 431 
27 (69.2%, Table 1) of these samples (scores 1-3; Fig. 6A). Distribution of Stat3 nuclear 432 
pStat3Ser727 scores is shown in Figure 6B, and was similar to the one distribution previously 433 
reported for pStat3Tyr705 (Sato et al. 2011). When we examined the possible correlation 434 
among various clinicopathological parameters, we found that the nuclear localization of 435 
pStat3Ser727 significantly correlated with the presence of PR (P=0.027, Table 1). In fact, 436 
among the PR positive tumors, 22 out of 27 (81%) presented pStat3Ser727 nuclear 437 
localization. In contrast among the PR negative tumors only 37% presented pStat3Ser727 438 
nuclear localization (3 out of 8 tumors). We observed a trend for nuclear localization of 439 
pStat3Ser727 and ER expression, but the difference was not statistically significant 440 
(P=0.061). 441 
442 
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DISCUSSION 443 
In the present study we have shown that progestins are able to induce Stat3Ser727 444 
phosphorylation and that the c-Src/p42/p44 MAPK signalling pathway is involved in this 445 
phosphorylation event. In addition we have shown that Ser727 phosphorylation of Stat3 is 446 
required to induce cyclin D1 expression and to promote in vivo and in vitro breast cancer cell 447 
proliferation. These findings contribute to a better understanding of the participation of 448 
nongenomic progestins effect on breast cancer growth, showing that phosphorylation ofStat3 449 
in serine 727 is an essential event. 450 
A wide variety of kinases participating in Ser727 phosphorylation of Stat3 have been 451 
described in diverse cell types and stimuli such as MAPK, including p42/p44 MAPK, c-Jun 452 
kinases (JNK), p38 MAPK, PKCε and mTOR kinases (Decker et al. 2000). Recently, PKCε 453 
oncogenic activity was disclosed to proceed through the activation of Raf-1, MEK-1 and 454 
p42/p44MAPK to phosphorylate Stat3 at Ser727 residue. The event of Stat3Ser727 455 
phosphorylation was recognized to be essential for PKCε induced invasion in various human 456 
cancer (Aziz et al. 2010). With respect to the rapid signaling of PR, Auricchio and co-workers 457 
described a nongenomic effect of progestins that accounts for the activation of the c-458 
Src/p21ras/p42/p44MAPK signaling pathway in human breast cancer cell line T-47D (Ballare 459 
et al. 2003, Migliaccio et al. 1998). Moreover, our own previous findings demonstrate that 460 
progestins induce Stat3Tyr705 phosphorylation through the activation of the c-Src/Jak 461 
signaling cascade (Proietti et al. 2005). These effects of progestins on cell signaling in the 462 
absence of transcription are dependent on classical PR. Indeed human PR has, in the amino 463 
terminal domain, a polyproline motif (amino acids 421-428) that mediates direct interaction 464 
of PR with the SH3 domain of the nonreceptor tyrosine kinase c-Src, and activates this kinase 465 
by an SH3 domain displacement mechanism (Boonyaratanakornkit et al. 2001). Evidence 466 
confirms that c-Src activation is mediated by PR outside the nucleus, supporting the fact that 467 
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only PR-B can stimulate c-Src and not PR-A, which is mostly nuclear (Boonyaratanakornkit 468 
et al. 2007). In our reconstitution experiments in human PR null T-47D-Y breast cancer cells 469 
with the PR-BmPro, who lacks the polyproline motifs necessary for PR activation of c-Src, 470 
MPA treatment was not able to phosphorylate Stat3 at Ser727 residue. Interstingly, we found 471 
that MPA induces p42/p44 MAPK activation via c-Src in C4HD cells.  Although mouse PR 472 
lacks the polyproline motif, we have already demonstrated that MPA induces c-Src activation 473 
and p42/p44 MAPK in C4HD murine cells (Proietti et al. 2005, Carnevale et al. 2007). 474 
Moreover, we recently described the importance of phosphorylation on Ser 294 in human and 475 
mouse PR regulation of c-Src activity in response to heregulin (Proietti et al. 2009). Taking 476 
into account that MPA induces phosphorylation of PR on Ser 294 residue (Shen et al. 2001), 477 
this activated receptor could in turn also induce c-Src activation. 478 
 The evidence provided here supports a direct link between c-Src/p42/p44 MAPK and 479 
Stat3Ser727 phosphorylation. First, addition of the p42/p44 MAPK pathway inhibitor, U0126, 480 
resulted in abolishment of MPA capacity to phosphorylate Stat3Ser727.  Second, inhibition of 481 
c-Src activity by pharmacological inhibitors (PP2 and dasatinib) prevented MPA-induced 482 
p42/p44 MAPK activation and Stat3Ser727 phosphorylation. Finally, the in vitro 483 
phosphorylation assay indicated that MPA-activated p42/p44 MAPK can phosphorylate Stat3 484 
at Ser727 residue. Together, all these data strongly suggest that MPA triggers a signaling 485 
cascade inducing the sequential activation of c-Src, p42/p44MAPK that leads to Stat3Ser727 486 
phosphorylation both in human and mouse breast cancer cells. There are several reports 487 
supporting the fact that the biological involvement of Stat3Ser727 phosphorylation is to 488 
achieve the full transcriptional activation of Stat3 (Decker et al. 2000, Wen et al. 1995). 489 
Indeed, Shen et al. observed a marked reduction in Stat3 transcriptional activation in vivo 490 
when expressing the Stat3S727A mutant (Shen et al. 2004). As described before, the 491 
dominant negative mechanism of Stat3S727A relies on the ability to form homo- or 492 
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heterodimers with the endogenous wild-type protein, resulting in poor transcriptional 493 
activation (Bromberg et al. 1998, Zhang et al. 1996). On the other hand, Ser727-494 
phosphorylated Stat3 has also been suggested to mediate activation of transcription without 495 
detectable Tyr705 phosphorylation, as recently reported in chronic lymphocytic leukemia 496 
(Hazan-Halevy et al. 2010). Collectively, the available data indicate that the effect of 497 
Stat3Ser727 phosphorylation probably depends on the type of extracellular stimulus, cell 498 
type, and the activation status of the cell studied. Our results indicate that the presence of the 499 
Stat3S727A mutant abolished the transcriptional activity of the m67 reporter and of cyclin D1 500 
promoter. Moreover, our ChIP results on the cyclin D1 GAS site confirmed that Stat3 was not 501 
recruited to the promoter in the presence of Stat3S727A.  502 
It is well acknowledged that cyclin D1 is a requirement for breast carcinogenesis (Yu et al. 503 
2001). Here we showed that progestin induction of cyclin D1 gene expression is dependent on 504 
the c-Src/p42/p44 MAPK/pStat3Ser727 signaling cascade. Moreover, in our present study we 505 
found that this phosphorylation event is essential for progestin-induced breast cancer 506 
proliferation. We found that the presence of phosphorylated Stat3 at Ser727 is a requisite for 507 
progestin stimulation of in vitro and in vivo breast cancer growth. These findings support new 508 
avenues for therapeutic approaches targeting p42/p44MAPK signaling, like the MEK 509 
inhibitor AZD6244 that is now in phase II trials for several malignancies (Patel et al. 2012, 510 
O'Neil et al. 2011). 511 
Interestingly, our clinical data show for the first time that there is an association between 512 
increased levels of pStat3Ser727 and PR expression in invasive ductal breast carcinomas. 513 
Indeed, we observed that 81% of PR positive tumors also express nuclear pStat3Ser727, 514 
which provides support to accumulating evidence showing Stat3 activation in breast tumor 515 
samples (Dolled-Filhart et al. 2003, Sato et al. 2011). Moreover, our data suggest that 516 
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phosphorylation in Ser727 residue may be attributable to the presence of PR and consequently 517 
to progestin action in breast cancer patients.  518 
In conclusion, our present findings reveal that acting through a nongenomic signaling 519 
cascade, progestin is able to phosphorylate Stat3 in Ser727 residue leading to in vivo cyclin 520 
D1 up-regulation and breast cancer growth. Thus, our results presented here encourage further 521 
exploration of the potential therapeutic value of targeting Stat3 through inhibition of upstream 522 
p42/p44 MAPK signaling in PR-positive breast tumors. 523 
524 
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Supplementary data: See two supplementary tables. 525 
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FIGURE LEGENDS 710 
 711 
Figure 1 MPA induces Stat3Ser727 phosphorylation through the classical PR (A) MPA 712 
induces Stat3 phosphorylation on Ser727. C4HD cells (upper panel) or T-47D cells (lower 713 
panel) were treated with MPA for different time points. Western blots (WB) were performed 714 
with pStat3Ser727 or pp42/p44 MAPK antibodies, and filters were reprobed with total Stat3 715 
and p42/p44 MAPK antibodies. β-tubulin is shown as loading control. Data analysis showed 716 
that the increases in p42/p44 MAPK phosphorylation in cells treated with MPA compared 717 
with the levels of nontreated cells were signiﬁcant (P<0.001). (B) and (C) MPA-induced 718 
Stat3Ser727 phosphorylation is mediated via the classical PR. (B) C4HD cells were treated 719 
with MPA for 10 min or pretreated with RU486 for 90 min before MPA treatment (left). 720 
C4HD cells were transfected with PR siRNA or control siRNA before MPA stimulation (10 721 
min) (right). WB were performed with pStat3Ser727 antibodies, and filters were reprobed 722 
with total Stat3 antibodies. WB shows the effects of siRNAs on PR expression. Data analysis 723 
showed that the inhibition of MPA induced Stat3 phosphorylation levels caused by PR siRNA 724 
were signiﬁcant (P<0.001). (C) T-47D-Y cells were treated with MPA or were transfected 725 
with the PR-B isoform before MPA treatment. In all cases, bands were quantiﬁed using Image 726 
J and phospho-protein bands values were normalized to total protein bands. Nontreated cell 727 
samples were set as 1.0. (A-C) Signal intensities of phospho Stat3 Ser727 bands normalized 728 
to total Stat3 bands are graphically represented in bar plots (*P< 0.05, 729 
**P<0.01,***P<0.001). Data are presented as mean±SEM of three experiments. 730 
Figure 2 MPA induces Stat3Ser727 phosphorylation through Src/p42/p44 MAPK activation 731 
pathway. (A) and (B) c-Src mediates MPA-induced p42/p44 MAPK activation which leads to 732 
Stat3Ser727 phosphorylation. (A) T-47D-Y cells were transfected with the PR-BmPro mutant 733 
and were then treated with MPA. T-47D cells are shown as Stat3Ser727 phosphorylation 734 
control. (B) T-47D cells were treated with MPA for 15 min (pStat3Ser727) or 2 min (pSrc 735 
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and pp42/p44 MAPK) or preincubated for 90 min with PP2 or Dasatinib before MPA 736 
treatment (left panel). C4HD cells were treated with MPA for 10 min or preincubated for 90 737 
min with PP2 before MPA treatment (right panel). WB were performed with phospho-738 
antibodies, and filters were reprobed with the respective total protein antibody. (C) and (D) 739 
p42/p44 MAPK mediates MPA-induced Stat3Ser727 phosphorylation. (C) C4HD cells were 740 
treated with MPA or preincubated for 90 min with U0126 before MPA treatment. WB were 741 
performed against pStat3Ser727 (upper panel) and pp42/44 MAPK (lower panel) and filters 742 
were reprobed with the respective total protein antibody. (A-C) In all cases, bands were 743 
quantiﬁed using Image J and phospho-protein bands values were normalized to total protein 744 
bands. Nontreated cell samples were set as 1.0. Signal intensities of phospho Stat3 Ser727 745 
bands normalized to total Stat3 bands are graphically represented in bar plots 746 
(**P<0.01,***P<0.001). Data are presented as mean±SEM of three experiments. Data 747 
analysis showed that the increases in p42/p44 MAPK and c-Src phosphorylation in cells 748 
treated with MPA compared with the levels of nontreated cells were signiﬁcant (P<0.001). 749 
(D) A cold in vitro phosphorylation assay was performed with T-47D cells preincubated or 750 
not with U0126 and then treated with MPA for 2 min. p42/p44 MAPK were 751 
immunoprecipitated from each treatment and Stat3 immunoprecipitated from nontreated T-752 
47D cells was used as substrate. Shown are WBs of Stat3, anti-phospho Stat3Ser727, anti-753 
phospho p42/p44 MAPK and p42/p44 MAPK. Signal intensities of phospho Stat3 Ser727 754 
bands were analyzed by densitometry and normalized to total immunoprecipitated Stat3 755 
bands. Nontreated cell samples were set as 1.0. This experiment was repeated three times with 756 
similar results. IP, immunoprecipitation.  757 
Figure 3 MPA effects on Stat3Ser727 cellular localization (A) C4HD cells were treated with 758 
MPA for 10 and 15 min, and nuclear and cytosolic protein extracts were analyzed by WB. 759 
pStat3Ser727 blot was reprobed with a Stat3 antibody. Total cell lysates treated with MPA 760 
Page 31 of 41
  
32
were blotted in parallel. β-tubulin was used to control cellular fractionation efficiency. Bands 761 
were quantiﬁed using Image J and values of nuclear and cytosolic protein bands were 762 
normalized to actin. Fold changes in nuclear and cytosolic phospho Stat3 Ser727 and total 763 
Stat3 are graphically represented in bar plots (*P<0.05, **P<0.01,***P<0.001). Data are 764 
presented as mean±SEM of three experiments. (B) T-47D cells were treated with 10 nM MPA 765 
for 10 and 15 min and pStat3Ser727 (green) was localized by immunofluorescence and 766 
confocal microscopy. Nuclei were stained with propidium iodide (red). Merged images show 767 
nuclear localization of pStat3Ser727 at 10 and 15 min of MPA treatment. The experiments 768 
were repeated five times, with similar results.  769 
Figure 4 Serine 727 phosphorylation of Stat3 is a requirement for MPA-induced Stat3 full 770 
transcriptional activation (A) C4HD cells were transfected with a luciferase reporter plasmid 771 
containing four copies of the m67 high-affinity binding site (4xm67-tk-luc) and a renilla 772 
expression vector as an internal control. Cells were co-transfected with the empty vector 773 
(pcDNA 5/FRT) or Stat3WT or Stat3S727A expression vectors. After transfection, cells were 774 
treated with MPA for 24 h. Results are presented as the fold induction of luciferase activity 775 
with respect to control cells not treated with MPA. Data shown represent the mean data from 776 
three independent experiments for each cell type ± SEM. Results are presented as the fold 777 
induction of luciferase activity with respect to cells without MPA treatment. Statistical 778 
significances are calculated against cells without MPA treatment (*P<0.05,**P<0.01). (B) 779 
MPA induces cyclin D1 promoter activation via Stat3Ser727 phosphorylation. Cells were 780 
transfected with a 1,745-bp-length human cyclin D1 promoter luciferase construct, which 781 
contains Stat3 binding sites (GAS) and lacks progesterone responsive elements (PRE) 782 
(CyclinD1-luc). Cells were co-transfected with the empty vector or Stat3WT or Stat3S727A 783 
expression vectors. After transfection, cells were treated with MPA for 24 h. Results are 784 
presented as the fold induction of luciferase activity with respect to control cells not treated 785 
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with MPA. Data shown represent the mean data from three independent experiments for each 786 
cell type ± SEM. Statistical significances are calculated against control cells (*P<0.05, 787 
**P<0.01). (C) MPA induces cyclin D1 protein expression via Stat3Ser727 phosphorylation. 788 
T-47D and C4HD cells were transfected with the empty vector or Stat3WT or Stat3S727A 789 
expression vectors, and were then treated with MPA for 24 h. Cyclin D1 protein expression 790 
was analyzed by WB. Bands were quantiﬁed using Image J and cyclin D1 protein values were 791 
normalized to β-tubulin. Nontreated cell samples were set as 1.0. These experiments were 792 
repeated four times with similar results. Data analysis showed that the increases in cyclin D1 793 
expression induced by MPA treatment in cells transfected with the empty vector and with 794 
Stat3WT compared with the levels of nontreated cells and the inhibition of MPA effect 795 
caused by transfection with Stat3S727A were signiﬁcant (P<0.01). (D) MPA induces in vivo 796 
binding of Stat3 to the cyclin D1 promoter via pStat3Ser727. Recruitment of Stat3 to the 797 
cyclin D1 promoter was analyzed by ChIP of cells transfected with the empty vector or 798 
Stat3WT or Stat3S727A expression vectors and treated with MPA for 30 min. DNA was 799 
immunoprecipitated with total Stat3 antibody and was ampliﬁed by qPCR using primers 800 
ﬂanking the GAS sites. The arbitrary qPCR number obtained for each sample was normalized 801 
to the input, setting the value of the nontreated sample as 1. Data are expressed as fold 802 
chromatin enrichment over nontreated cells (**P<0.01). Experiments were repeated three 803 
times with similar results. 804 
Figure 5 Serine 727 phosphorylation is required for in vitro and in vivo breast cancer 805 
proliferation (A) T-47D and C4HD were transfected with either the empty vector 806 
(pcDNA5/FRT) or Stat3WT or Stat3S727A expression vectors and were treated with MPA 807 
for 24 or 48 h respectively. Incorporation of [
3
H]thymidine was used as a measure of DNA 808 
synthesis. Data are presented as mean ± SD of octuplicates. Statistical significances are 809 
calculated against the MPA-treated empty vector or Stat3WT-transfected cells (*P<0.001). 810 
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The experiments were repeated three times with similar results. (B) T-47D cells were 811 
transfected with Stat3WT or Stat3S727A expression vectors before MPA stimulation for 24 h, 812 
and were then stained with propidium iodide and analyzed for cell cycle distribution by flow 813 
cytometry. Data from the experiments shown are representative of those from a total of four 814 
experiments. (C) Effect of blockade of Stat3Ser727 phosphorylation on C4HD in vivo growth. 815 
C4HD cells (10
6
) from each experimental group (empty vector-C4HD or Stat3S727A-C4HD) 816 
were inoculated subcutaneously (s.c.) into mice treated with MPA. Each point represents the 817 
mean volume of 5 tumors ± SD. The experiment was repeated twice with similar results (* 818 
P<0.05). (D) Stat3Ser727 phosphorylation and cyclin D1 expression in C4HD tumors. Tumor 819 
lysates were analyzed by WB with pStat3S727 or cyclin D1 antibodies. Shown are two 820 
representative samples of mice injected with empty vector-C4HD cells (lanes 1 and 2), and 821 
with Stat3S727A- C4HD cells (lanes 3 and 4). Membranes were then stripped and hybridized 822 
with an anti Stat3 or anti actin antibodies. In all cases, bands were quantiﬁed using Image J, 823 
phospho Stat3 protein band values were normalized to total Stat3 protein bands, and cyclin 824 
D1 bands were normalized to actin bands. The first sample of empty vector-C4HD cells were 825 
set as 1.0.There was significant inhibition of cyclin D1 and Stat3Ser727 phosphorylation in 826 
mice injected with C4HD-Stat3S727A cells with respect to mice injected with empty vector 827 
C4HD cells (P<0.01). 828 
Figure 6 Cellular localization of pStat3Ser727 in invasive breast carcinomas (A) Nuclear 829 
pStat3Ser727 score. Immunofluorescence staining of breast cancer specimens with anti 830 
pStat3Ser727 antibody (green) and confocal analysis (see Materials and Methods for antibody 831 
specifications). Nuclei were stained with propidium iodide (red). Merged images show 832 
nuclear localization of pStat3Ser727 in tumor samples. (B) Distribution of nuclear 833 
pStat3Ser727 immunofluorescence staining scores in invasive breast carcinomas (0-3). 834 
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Table 1  Association between nuclear pStat3Ser727 expression and 
clinicopathological characteristics in breast cancer
Total cohort
(N= 39)
  pStat3Ser727, n (%) P  value
a
Negative Positive
Total patients N (%) 12 (30.8) 27 (69.2)
Tumor size
   ≤ 20mm 5 (41.7) 14 (56.0) 0,321
   >20mm 7 (58.3) 11 (44.0)
 Total N (%) 12 (32.4) 25 (67.6)
Nodal metastasis
   Negative 8 (66.7) 14 (56.0) 0.401
   Positive 4 (33.3) 11 (44.0)
 Total N (%) 12 (32.4) 25 (67.6)
Distant metastasis
   M0 11 (91.7) 26 (100.0) 0.316
   M1 1 (8.3) 0 (0)
 Total N (%) 12 (31.6) 26 (68.4)
Clinical stage
   I 4 (33.3) 11 (40.7) 0.472
   II+III+IV 8 (66.7) 16 (59.3)
 Total N (%) 12 (30.8) 27 (69.2)
Tumor grade
  Well to moderately differentiated
b
5 (41.7) 17 (70.8) 0.092
  Poorly differentiated 7 (58.3) 7 (29.2)
 Total N  (%) 12 (33.3) 24 (66.7)
ER
c 
expression
   Negative 3 (30.0) 1 (4.0) 0.061
   Positive 7 (70.0) 24 (96.0)
 Total N 10 (28.6) 25 (71.4)
PR
d 
expression
   Negative 5 (50.0) 3 (12.0) 0.027
   Positive 5 (50.0) 22 (88.0)
 Total N 10 (28.6) 25 (71.4)
 
a 
Fisher's exact test. 
b
 Well to moderately differentiated: Tumor grade 1+2, Poorly differentiated: Tumor 
grade 3.
 c
ER: Estrogen Receptor. 
d
PR: Progesterone Receptor 
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